tradingkey.logo
tradingkey.logo
Search

Rani Therapeutics Holdings Inc

RANI
Add to Watchlist
0.526USD
+0.001+0.19%
Close 11-13 16:00(ET)
73.32MMarket Cap
LossP/E TTM

Rani Therapeutics Holdings Inc (RANI) Stock Price Target & Forecast

Analyst Rating

Based on 5 analysts giving stock ratings to Rani Therapeutics Holdings Inc in the past month.

Buy
0 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
6.250USD+959.32%

RANI Analyst Recommendation Trends

In the current month, RANI has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RANI average Analyst price target in the last month is 6.250.

2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
Strong Buy
0
0
0
0
0
0
0
0
Buy
5
5
4
4
4
4
3
3
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
5
5
4
4
4
4
3
3

RANI Analyst Rating for Peer Comparison

Updated: Nov 5, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22

Financial Forecasting

Based on analysts' estimates, RANI EPS is projected to reach -0.048 in FY2026Q4, following reported EPS of -0.039 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.

EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.04
-0.05
-0.05
-0.05
-0.05
Actual
-0.04
-0.04
-0.04
--
--
Surprise
+13.18%
+21.02%
+18.23%
--
--

FAQs

What is Rani Therapeutics Holdings Inc's expected revenue for the next quarter?

Rani Therapeutics Holdings Inc's expected revenue is 1.60M.

What is Rani Therapeutics Holdings Inc's price target?

Analysts forecast that Rani Therapeutics Holdings Inc's price target is USD 6.25, with the highest forecast at USD 9.00 and the lowest forecast at USD 5.00.

How have Rani Therapeutics Holdings IncRANI's recent earnings per share performed?

The market expectation was USD -0.04, while Rani Therapeutics Holdings IncRANI's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD -0.05.

What is the analyst rating for Rani Therapeutics Holdings Inc?

Based on the ratings of Rani Therapeutics Holdings Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.